Daniel Camacho, MD, PhD
he/him/his
Psychiatry ResidentCards
About
Research
Publications
2026
Negative regulation of human IL-33 in endothelium during allergic airway inflammation
Hollinger MK, Howard CL, Decker DC, Blaine KM, Aneas I, Grayson EM, Velez TE, Oliveira FA, Hannan RT, Camacho DF, Verhoef PA, Hrusch CL, Griffes RS, Sturek JM, Nobrega MA, Schoettler N, Sperling AI. Negative regulation of human IL-33 in endothelium during allergic airway inflammation. JCI Insight 2026, 11: e190418. DOI: 10.1172/jci.insight.190418.Peer-Reviewed Original ResearchNegative regulation of human IL-33 in endothelium during allergic airway inflammation
Hollinger M, Howard C, Decker D, Blaine K, Aneas I, Grayson E, Velez T, Oliveira F, Hannan R, Camacho D, Verhoef P, Hrusch C, Griffes R, Sturek J, Nobrega M, Schoettler N, Sperling A. Negative regulation of human IL-33 in endothelium during allergic airway inflammation. JCI Insight 2026, 11: e190418. PMID: 42100869, PMCID: PMC13232004, DOI: 10.1172/jci.insight.190418.Peer-Reviewed Original ResearchConceptsNegative regulatorIL-33Noncoding regionsPathogen defenseHuman genomeMurine genomeReporter strainMurine locusSpecies-specific tropismExpression in vivoFluorescent reportersReporter expressionLung IL-33Development of allergic responsesAllergic airway inflammationGenomeHuman endothelial cell lineHuman IL-33Cell typesExogenous IL-33IL33 expressionCell linesLociEndothelial cell lineBarrier homeostasis
2024
IL-33 downregulates human IL-33 expression in the pulmonary vasculature during allergic airway inflammation
Hollinger M, Howard C, Decker D, Blaine K, Hrusch C, Grayson E, Aneas I, Camacho D, Schoettler N, Ober C, Nobrega M, Sperling A. IL-33 downregulates human IL-33 expression in the pulmonary vasculature during allergic airway inflammation. The Journal Of Immunology 2024, 212: 0512_5695-0512_5695. DOI: 10.4049/jimmunol.212.supp.0512.5695.Peer-Reviewed Original ResearchAllergic airway inflammationIL-33Regulatory region in vivoNegative regulatorAirway inflammationIL33 expressionHuman airway epithelial cellsCell typesElements in vivoAirway epithelial cellsIL-33 expressionIL-33 proteinNegative feedback loopIn vitroTreatment in vivoPathogen defenseRegulatory elementsRegulatory regionsEnhancer elementsRegion in vivoHouse dust mitePulmonary vasculatureReporter miceLung endotheliumMRNA instability
2022
IRF4 expression by lung dendritic cells drives acute but not Trm cell–dependent memory Th2 responses
Camacho DF, Velez TE, Hollinger MK, Wang E, Howard CL, Darnell EP, Kennedy DE, Krishack PA, Hrusch CL, Clark MR, Moon JJ, Sperling AI. IRF4 expression by lung dendritic cells drives acute but not Trm cell–dependent memory Th2 responses. JCI Insight 2022, 7: e140384. DOI: 10.1172/jci.insight.140384.Peer-Reviewed Original ResearchIRF4 expression by lung dendritic cells drives acute but not TRM-dependent memory Th2 responses
Camacho D, Velez T, Hollinger M, Wang E, Howard C, Darnell E, Kennedy D, Krishack P, Hrusch C, Clark M, Moon J, Sperling A. IRF4 expression by lung dendritic cells drives acute but not TRM-dependent memory Th2 responses. JCI Insight 2022, 7: e140384. PMID: 36194494, PMCID: PMC9675458, DOI: 10.1172/jci.insight.140384.Peer-Reviewed Original ResearchConceptsInterferon regulatory factor 4Interferon regulatory factor 4 expressionMemory responsesTh2 responsesT cellsEffector T cellsT cell primingLung dendritic cellsDraining Lymph NodesTranscription factor interferon regulatory factor 4Response to allergenImpaired recruitmentRegulatory factor 4CDC2 developmentMature DCTh2 primingTh2 inductionDendritic cellsLymph nodesEffector responsesMouse modelAllergic responsesLungType 2Factor 4
2021
Inhibition of TH2 responses by a secreted component of a common farm bacterium
Hollinger M, Camacho D, Hrusch C, Barron G, Velez T, Zamora-Pineda J, Knight K, Sperling A. Inhibition of TH2 responses by a secreted component of a common farm bacterium. The Journal Of Immunology 2021, 206: 94.16-94.16. DOI: 10.4049/jimmunol.206.supp.94.16.Peer-Reviewed Original ResearchTh2 responsesHouse dust mite (HDM)-sensitized miceInhibition of Th2 responsesHygiene hypothesisMouse model of asthmaReduced prevalence of asthmaModel of asthmaTh2-type inflammationExposure to environmental microbesDendritic cellsNon-farming counterpartsTh subsetsIncidence of asthmaTh2 infiltrationAllergic asthmaInnocuous antigensPrevalence of asthmaMouse modelAllergic diseasesMiceAsthma diagnosisReduced prevalenceProtective effectAsthmaTh2Pro-lymphangiogenic VEGFR-3 signaling modulates memory T cell responses in allergic airway inflammation
Maisel K, Hrusch CL, Medellin JE, Potin L, Chapel DB, Nurmi H, Camacho DF, Gleyzer R, Alitalo K, Sperling AI, Swartz MA. Pro-lymphangiogenic VEGFR-3 signaling modulates memory T cell responses in allergic airway inflammation. Mucosal Immunology 2021, 14 DOI: 10.1038/s41385-020-0308-4.Peer-Reviewed Original Research
2020
Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and T <sub>H</sub> 17 responses
Si Y, Tian Q, Zhao F, Kelly SH, Shores LS, Camacho DF, Sperling AI, Andrade MS, Collier JH, Chong AS. Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and T H 17 responses. Science Advances 2020, 6: eaba0995. DOI: 10.1126/sciadv.aba0995.Peer-Reviewed Original ResearchAdjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and TH17 responses
Si Y, Tian Q, Zhao F, Kelly S, Shores L, Camacho D, Sperling A, Andrade M, Collier J, Chong A. Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and TH17 responses. Science Advances 2020, 6: eaba0995. PMID: 32821819, PMCID: PMC7413739, DOI: 10.1126/sciadv.aba0995.Peer-Reviewed Original ResearchConceptsDendritic cell activationMucosal barrier surfacesSelf-assembling nanofiber scaffoldCD103+Th17 responsesNanoparticle vaccineDendritic cellsNanoparticulate vaccinesVaccine reactogenicityExogenous adjuvantLocal inflammationProtective immunityCell activationVaccine antigensBacterial infectionsSubunit vaccineInnate immunityVaccineImmunityImmunogenicityAdjuvantBarrier surfacesAntigenDelivery systemCD80Leveraging Framework Instability: A Journey from Energy Storage to Drug Delivery
Matzger A, Suresh K, López-Mejías V, Roy S, Camacho D. Leveraging Framework Instability: A Journey from Energy Storage to Drug Delivery. Synlett 2020, 31: 1573-1580. DOI: 10.1055/s-0040-1707139.Peer-Reviewed Original ResearchAmorphous pharmaceuticalsMetal-organic frameworksEnergy storage materialsDissolution rateStorage materialsAmorphous form stabilityOral bioavailabilityFramework instabilityEnergy storageFast dissolution ratePorous solidsAmorphous formDrug delivery vehiclesForm stabilitySolubilityStabilityPharmaceuticalsDrug deliveryBioavailabilityPhysical stabilityEnergy
Academic Achievements & Community Involvement
News
News
- June 30, 2026
Department of Psychiatry Honors Residents, Fellows, Faculty, Staff at 2026 Annual Commencement Ceremonies
- January 15, 2026
Yale Psychiatry Trainees Match to Fellowship Programs
- March 20, 2025
Camacho, Kozar, Cheung Chosen for Membership in AAGP Scholars Program
- June 21, 2024
Department of Psychiatry Honors Residents, Fellows, Faculty, Staff at 2024 Annual Commencement Ceremonies